8 results on '"Concepción Moll"'
Search Results
2. Emergency medicine questions on the entrance examination for medical internships and residency training in Spain: analysis of changes between 2010 and 2019
- Author
-
Inés María, Fernández-Guerrero, Alba María, Ruiz Allende, Luis, Contreras Briones, Concepción, Moll Tudurí, Francisco Javier, Martín-Sánchez, and Òscar, Miró
- Subjects
Emergency Medical Services ,Spain ,Emergency Medicine ,Humans ,Internship and Residency ,Retrospective Studies - Abstract
To investigate the presence of fundamental concepts in emergency medicine on the entrance examination taken by candidates for medical internships and residency training in Spain, and to identify changes over time.Longitudinal retrospective study. Three independent researchers reviewed questions on the entrance examinations of the past 10 years (2010-2019) and classified them as directly, indirectly, or not related to emergency medicine. The topics of directly related questions were also classified according to the categories listed in Tintinalli's Emergency Medicine and subject areas in the Citation Index Expanded (SCIE) of the Web of Science. Changes in the number of questions and range of topics were analyzed with simple linear regression models.A total of 2300 questions were reviewed; 487 (22%) were directly related to emergency medicine, and 313 of them specifically referred to an emergency or urgent care setting. The proportion of directly related questions held steady over the 10-year period (P=.172). The most frequently mentioned categories listed by Tintinalli were cardiovascular (12.2%), infectious (11.1%), and gastrointestinal (10.9%) emergencies, and no significant differences were noted over time. However, proportions assigned to the SCIE categories did change over time, as follows. Questions about emergency care in general (11.9% during the period overall) increased significantly with time (P=.005) whereas cardiovascular questions (11.3%) decreased (P=.037). The proportion of infectious disease topics remained the same (10.7%).Even though emergency medicine is not a recognized specialty for medical residency training in the public health system, questions on emergencies are considered important for evaluating candidates, judging by the high percentage of questions on the examinations.Investigar la presencia del cuerpo doctrinal de la Medicina de Urgencias y Emergencias (MUE) en el examen de acceso a médico interno residente (MIR) en España y su evolución en el tiempo.Estudio longitudinal retrospectivo. Tres investigadores revisaron independientemente las preguntas de los exámenes MIR de los últimos 10 años (2010-2019) y las clasificaron por acuerdo mayoritario como directamente, indirectamente o no relacionadas con la MUE. La temática de las preguntas directamente relacionadas con la MUE se clasificó según el índice del libro de texto de MUE de Tintinalli y según la clasificación de las áreas de la base Science Citation Index Expanded (SCIE) de la Web of Science. La evolución temporal de la presencia y la temática de la MUE se analizó mediante regresión lineal simple.Se revisaron 2.300 preguntas: 487 (22%) estaban directamente relacionadas con la MUE (313 citaban específicamente el escenario de urgencias o emergencias). La presencia de preguntas directamente relacionadas con la MUE se mantuvo constante entre 2010-2019 (p = 0,172). Siguiendo la clasificación de Tintinalli, las temáticas más frecuentes de estas preguntas fueron urgencias cardiovasculares (12,2%), infecciosas (11,1%) y gastrointestinales (10,9%), sin cambios significativos entre 2010-2019, mientras que siguiendo la clasificación del SCIE, estas temáticas fueron urgencias (11,9%, que aumentó significativamente durante el periodo, p = 0,005), cardiovascular (11,3%, que descendió, p = 0,037) y enfermedades infecciosas (10,7%, sin cambios durante el periodo).La MUE, a pesar de no estar reconocida como una especialidad formativa por la vía MIR, tiene una elevada relevancia para la administración sanitaria a la hora de seleccionar a los MIR, que inician su formación especializada en el sistema público de salud, a juzgar por su elevada presencia en el examen anual al que se somete a los candidatos.
- Published
- 2020
3. Emergency department visits for transient global amnesia alone or in association with substance abuse
- Author
-
Concepción, Moll Tudurí, Emilio José, Salgado García, Daniel, Santana Moreno, Ona, Escoda Turón, Rosa, Escoda Turón, and Santiago, Nogué Xarau
- Subjects
Adult ,Aged, 80 and over ,Male ,Analysis of Variance ,Marijuana Abuse ,Adolescent ,Alcohol Drinking ,Amphetamine-Related Disorders ,Sex Offenses ,Middle Aged ,Cocaine-Related Disorders ,Young Adult ,Amnesia, Transient Global ,Prevalence ,Humans ,Female ,Emergency Service, Hospital ,Tomography, X-Ray Computed ,Aged ,Retrospective Studies - Abstract
To study the epidemiology of emergency department visits for transient global amnesia (TGA) by itself or associated with substance abuse or sexual assault.Retrospective study of cases treated from January to December 2018. Data for all patients with TGA were extracted, and cases were classified as associated with substance abuse (TGASUB), sexual assault (TGASEX), or neither (TGAONLY).A total of 287 TGA cases were found: 169 (58.9%) were TGASEX, 62 (21.6%) TGAONLY, and 56 (19.5%) TGASUB. Two hundred eighteen (76%) were female and 69 (24%) were male. Ages ranged from 16 to 90 years; 174 (60.6%) were under the age of 30 years. Two hundred one patients (72.8%) reported consuming alcohol; and 105 (49.1%) were positive on testing (mean blood alcohol concentration, 0.74 g/L; maximum, 3.9 g/L. Twenty patients (7.1%) reported using cannabis, and 39 (17.3%) had positive test results; 14 reported using cocaine (4.9%) and 28 (12.4%) tested positive; 5 (1.7%) reported using amphetamines and 20 (8.8%) tested positive. Fifty-eight (20.1%) had symptoms of intoxication. Four were admitted in coma. A computed tomography scan was ordered for 66 patients (23%), 7 patients were hospitalized, and none died.The prevalence of TGA is higher if cases of substance abuse and sexual assault are counted. Toxicolgy testing changes the epidemiology of TGA in emergencies.Conocer la epidemiología de las consultas en urgencias por amnesia global transitoria (AGT), ya sea pura, asociada al consumo de tóxicos o en el contexto de una agresión sexual.Estudio retrospectivo de enero a diciembre de 2018. Se revisaron las AGT atendidas en intoxicados (AGTtox), en víctimas de agresiones sexuales (AGTsex) y las amnesias puras (AGTpur), evaluando la presencia de tóxicos.Se identificaron 287 AGT: 169 AGTsex (58,9%), 62 AGTpur (21,6%) y 56 AGTtox (19,5%). De ellas, 218 (76%) fueron mujeres y la edad osciló entre 16 y 90 años (60,6% menores de 30 años). Reconocieron consumo de alcohol 201 casos (72,8%), con etanolemia positiva en 105 (49,1%) (media de 0,74 g/l y máxima de 3,9 g/l). Admitieron consumo de cannabis 20 pacientes (7,1%), con analítica positiva en 39 casos (17,3%); cocaína 14 (4,9%), con analítica positiva en 28 (12,4%), y anfetaminas 5 (1,7%), con analítica positiva en 20 (8,8%). Presentaron síntomas de intoxicación 58 casos (20,1%). Cuatro pacientes ingresaron en coma. Se realizó una tomografía computarizada (TC) craneal a 66 pacientes (23%), se hospitalizaron 7 y no hubo ningún fallecimiento.La prevalencia de AGT es mayor si se incluyen los intoxicados y las agresiones sexuales, modificando la determinación de tóxicos la epidemiología de la AGT en urgencias.
- Published
- 2019
4. FRI0336 Efficacy of tocilizumab in 31 patients with giant cell arteritis
- Author
-
Carmen González-Vela, E. Peirό, Isabel Hernández, J Ivorra, Vanesa Calvo-Río, Pau Lluch, E. Diez, Eva Perez-Pampin, Javier Loricera, Javier Narváez, L Domínguez-Casas, Antonio Mera, M. A. González-Gay, Clara Moriano, José L. Hernández, Concepción Moll, Jaime Calvo-Alén, A. Sanchez-Andrade, Santos Castañeda, A. Humbría, Francisco Ortiz-Sanjuán, Ricardo Blanco, Elena Aurrecoechea, Paloma Vela, and Alfonso Corrales
- Subjects
Giant cell arteritis ,chemistry.chemical_compound ,Pathology ,medicine.medical_specialty ,Tocilizumab ,chemistry ,business.industry ,Medicine ,business ,medicine.disease - Published
- 2017
5. RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database
- Author
-
Jenaro Graña Gil, Hèctor Corominas, Felipe Joaquín Rivas Santirso, Desireé Ruiz Vilchez, Silvia Garcia-Diaz, María Pilar Navarro Alonso, Jesús Carlos Fernández, Anna Martínez-Cristóbal, Rosa Expósito Moliner, Juan Víctor Tovar Beltrán, José Raúl Noguera Pons, Antonio Gracia Pérez, José Ramón Lamua Riazuelo, Arantxa Conesa Mateos, Jaime Calvo Alén, Delia Taverner Torrent, Raúl Cortés Verdú, Rosa García Portales, Alejandro Muñoz Jiménez, Juan José Lerma Garrido, Concepción Moll Turudi, Angel Aragón Díez, Ana Urruticoechea Arana, José Miguel Ruiz Martín, María Jesús Martínez Blasco, Amalia Sánchez-Andrade Fernández, RENACER StudyGroup, Sergi Ordoñez Palau, Noemí Patricia Garrido Puñal, Vicenç Torrente-Segarra, Noelia Vázquez Fuentes, Manuel Fernandez Prada, Carlos Tomás Roura, José Antonio González Ferrández, Raúl Veiga Cabello, Pedro Giralt Celiméndiz, Asunción Acosta Pereira, Silvia Paredes González-Albo, [Torrente-Segarra, Vicenc] Hosp Gen Hospitalet St Joan Despi Moises Broggi, Dept Rheumatol, C Avinguda Josep Molins 29-41, Lhospitalet De Llobregat 08906, Catalunya, Spain, [Corominas, Hector] Hosp Gen Hospitalet St Joan Despi Moises Broggi, Dept Rheumatol, C Avinguda Josep Molins 29-41, Lhospitalet De Llobregat 08906, Catalunya, Spain, [Urruticoechea Arana, Ana] Hosp Can Misses, Dept Rheumatol, Ibiza, Spain, [Sanchez-Andrade Fernandez, Amalia] Complejo Hosp Univ Lucus Augusti, Dept Rheumatol, Lugo, Spain, [Tovar Beltran, Juan Victor] Hosp Gen Univ Elche, Dept Rheumatol, Elche, Spain, [Noguera Pons, Jose Raul] Hosp Gen Univ Elche, Dept Rheumatol, Elche, Spain, [Munoz Jimenez, Alejandro] Hosp Univ Virgen del Rocio, Dept Rheumatol, Seville, Spain, [Garrido Punal, Noemi Patricia] Hosp Univ Virgen del Rocio, Dept Rheumatol, Seville, Spain, [Martinez-Cristobal, Anna] Hosp Ribera, Dept Rheumatol, Alzira, Spain, [Gonzalez Ferrandez, Jose Antonio] Hosp Univ Guadalajara, Dept Rheumatol, Guadalajara, Spain, [Fernandez Prada, Manuel] Hosp Univ Ceuta, Dept Rheumatol, Ceuta, Spain, [Vazquez Fuentes, Noelia] Hosp Gen Hospitalet St Joan Despi Moises Broggi, Dept Rheumatol, St Joan Despi, Spain, [Garcia-Diaz, Silvia] Hosp Gen Hospitalet St Joan Despi Moises Broggi, Dept Rheumatol, St Joan Despi, Spain, [Acosta Pereira, Asuncion] Hosp Santa Creu & Sant Pau, Dept Rheumatol, Barcelona, Spain, [Ruiz Martin, Jose Miguel] Hosp Viladecans, Dept Rheumatol, Viladecans, Spain, [Lamua Riazuelo, Jose Ramon] Hosp Univ Henares, Dept Rheumatol, Alcala De Henares, Spain, [Exposito Moliner, Rosa] Hosp Comarcal Laredo, Dept Rheumatol, Laredo, Spain, [Ruiz Vilchez, Desiree] Hosp Univ Reina Sofia, Dept Rheumatol, Cordoba, Spain, [Veiga Cabello, Raul] Hosp Fuenlabrada, Dept Rheumatol, Fuenlabrada, Spain, [Carlos Fernandez, Jesus] Complejo Hosp Univ A Coruna, Dept Rheumatol, La Coruna, Spain, [Giralt Celimendiz, Pedro] Hosp St Bernabe, Dept Rheumatol, Berga, Spain, [Cortes Verdu, Raul] Hosp Publ LluisAlcanyis de Xativa, Dept Rheumatol, Valencia, Spain, [Aragon Diez, Angel] Hosp Univ Getafe, Dept Rheumatol, Getafe, Spain, [Tomas Roura, Carlos] Hosp Comarcal Mora dEbre, Dept Rheumatol, Mora Debre, Spain, [Moll Turudi, Concepcion] Hosp Gen MateuOrfila, Dept Rheumatol, Maho, Spain, [Taverner Torrent, Delia] Hosp Univ Reus, Dept Rheumatol, Reus, Spain, [Paredes Gonzalez-Albo, Silvia] Hosp Univ Reus, Dept Rheumatol, Reus, Spain, [Rivas Santirso, Felipe Joaquin] Clin Dr Rivas, Dept Rheumatol, Segovia, Spain, [Lerma Garrido, Juan Jose] Hosp Gen Castellon, Dept Rheumatol, Castellon De La Plana, Spain, [Garcia Portales, Rosa] Hosp Virgen de la Victoria Malaga, Dept Rheumatol, Malaga, Spain, [Ordonez Palau, Sergi] Hosp Arnau Vilanova, Dept Rheumatol, Lleida, Spain, [Gracia Perez, Antonio] Clin Quiron Valencia, Dept Rheumatol, Valencia, Spain, [Conesa Mateos, Arantxa] Hosp Clin Valencia, Dept Rheumatol, Valencia, Spain, [Calvo Alen, Jaime] Hosp Sierrallana, Dept Rheumatol, Torrelavega, Spain, [Grana Gil, Jenaro] EOXI CHU A Coruna, Dept Rheumatol, La Coruna, Spain, [Navarro Alonso, Maria Pilar] Hosp Fuenlabrada, Dept Rheumatol, Madrid, Spain, and [Martinez Blasco, Maria Jesus] Hosp Univ Mostoles, Dept Rheumatol, Mostoles, Spain
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,Survival rate ,Efficacy ,College-of-rheumatology ,Clinical practice ,Logistic regression ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Long-term ,Internal medicine ,medicine ,030212 general & internal medicine ,Certolizumab pegol ,Rheumatoid arthritis ,skin and connective tissue diseases ,Prospective cohort study ,030203 arthritis & rheumatology ,Gisea registry ,Clinical-practice ,Danish danbio registry ,business.industry ,Certolizumab PEGol ,Adalimumab ,Alpha agents ,medicine.disease ,Discontinuation ,Japanese patients ,Anti-tnf therapy ,Plus methotrexate ,Physical therapy ,National database ,Observational study ,Safety ,business ,medicine.drug ,Spanish population - Abstract
To assess effectiveness and safety of certolizumab PEGol (CZP) in rheumatoid arthritis (RA) patients after 12 months of treatment and to detect predictors of response.Observational longitudinal prospective study of RA patients from 35 sites in Spain. Variables (baseline, 3- and 12-month assessment): sociodemographics, previous Disease Modifying Anti-Rheumatic Drug (DMARD) and previous Biological Therapies (BT) use; TJC, SJC, ESR, CRP, DAS28, SDAI. Response variables: TJC, SJC, CRP, ESR, and steroids dose reductions, EULAR Moderate/Good Response, SDAI response and remission, DAS28 remission. Safety variables: discontinuation due to side-effects. Descriptive, comparative and Logistic regression analyses were performed.We included 168 patients: 79.2% women, mean age 54.5 years (±13.2 SD), mean disease duration 7.5 years (±7.3 SD). Mean number of prior DMARD: 1.4 (±1.2 SD), mean number of prior BT was 0.8 (±1.1). Mean time on CZP was 9.8 months (±3.4 SD). A total of 71.4% were receiving CZP at 12-month assessment. Baseline predictors of response: lower prior number DMARD; low number prior BT; higher CRP, ESR, TJC, SJC, DAS28 and SDAI (p 0.05) scores. A 25/46.4% Moderate/Good Response, a 20% SDAI remission, and a 44% DAS28 remission were observed. We observed 48 discontinuations (28.6%), 31 due to partial or complete ineffectiveness, and 17 due to side-effects.CZP showed benefit in severe RA patients, with significant reduction of all effectiveness parameters, despite the high prevalence of previous BT exposure in our series. We found CRP, ESR, prior DMARD/BT number, TJC, SJC, DAS28, and SDAI as baseline predictors of response. CZP was mostly well tolerated.
- Published
- 2016
6. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients
- Author
-
C. Mata, Javier Narváez, Elvira Díez, Antonio Mera, Paloma Vela, Carmen González-Vela, A. Sanchez-Andrade, Santos Castañeda, A. Humbría, Elena Aurrecoechea, Ricardo Blanco, Trinitario Pina, Íñigo Hernández, Francisco Ortiz-Sanjuán, Peiró E, Miguel A. González-Gay, Eva Perez-Pampin, José L. Hernández, Pau Lluch, Vanesa Calvo-Río, Concepción Moll, Jaime Calvo-Alén, and Javier Loricera
- Subjects
Male ,medicine.medical_specialty ,Constitutional symptoms ,medicine.drug_class ,Giant Cell Arteritis ,Blood Sedimentation ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Polymyalgia rheumatica ,chemistry.chemical_compound ,Tocilizumab ,Rheumatology ,Prednisone ,Interquartile range ,Internal medicine ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Jaw claudication ,Giant cell arteritis ,Anesthesiology and Pain Medicine ,C-Reactive Protein ,Treatment Outcome ,chemistry ,Polymyalgia Rheumatica ,Corticosteroid ,Female ,business ,medicine.drug - Abstract
To assess the efficacy of tocilizumab (TCZ) in giant cell arteritis (GCA) patients with refractory disease and/or with unacceptable side effects due to corticosteroids.A retrospective multicenter open-label study on 22 GCA patients treated with TCZ at standard dose of 8mg/kg/month. The main outcomes were achievement of disease remission and reduction of corticosteroid dose.The mean age ± standard deviation of patients was 69 ± 8 years. The main clinical features at TCZ onset were polymyalgia rheumatica (n = 16), asthenia (n = 7), headache (n =5), constitutional symptoms (n = 4), jaw claudication (n = 2), and visual loss (n = 2). Besides corticosteroids and before TCZ onset, 19 of 22 patients had also received several conventional immunosuppressive and/or biologic drugs. Of 22 patients, 19 achieved rapid and maintained clinical improvement following TCZ therapy. Also, after a median follow-up of 9 (interquartile range: 6-19) months, the C-reactive protein level had fallen from 1.9 (1.2-5.4) to 0.2 (0.1-0.9)mg/dL (p0.0001) and the erythrocyte sedimentation rate decreased from 44 (20-81) to 12 (2-20)mm/1st hour (p = 0.001). The median dose of prednisone was also tapered from 18.75 (10-45) to 5 (2.5-10)mg/day (p0.0001). However, TCZ had to be discontinued in 3 patients due to severe neutropenia, recurrent pneumonia, and cytomegalovirus infection. Moreover, 1 patient died after the second infusion of TCZ due to a stroke in the setting of an infectious endocarditis.TCZ therapy leads to rapid and maintained improvement in patients with refractory GCA and/or with unacceptable side effects related to corticosteroids. However, the risk of infection should be kept in mind when using this drug in patients with GCA.
- Published
- 2014
7. RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database
- Author
-
V Torrente-Segarra, Vicenç Torrente-Segarra, A Urruticoechea Arana, Ana Urruticoechea Arana, A Sánchez-Andrade, Amalia Sánchez-Andrade Fernández, JV Tovar, Juan Víctor Tovar Beltrán, A Muñoz, Alejandro Muñoz Jiménez, A Martínez, Anna Martínez-Cristóbal, JA González, José Antonio González Ferrández, Manuel Fernández Prada, M Fernández, N. Vázquez, Noelia Vázquez Fuentes, Hèctor Corominas, H Corominas, Sílvia García-Díaz, S García-Díaz, A Acosta-Pereira, Asunción Acosta Pereira, José Miguel Ruiz Martín, JM Ruiz Martín, JR Lamua Riazuelo, José Ramón Lamua Riazuelo, Rosa Expósito Moliner, R Expósito, Desireé Ruiz Vilchez, D Ruiz Vilchez, R Veiga Cabello, Raúl Veiga Cabello, J Carlos Fernández, Jesús Carlos Fernández, José Raúl Noguera Pons, JR Noguera Pons, N Patricia Garrido Puñal, Noemí Patricia Garrido Puñal, Pedro Giralt Celiméndiz, P Giralt Celiméndiz, Raúl Cortés Verdú, R Cortés Verdú, Angel Aragón Díez, A Aragón Díez, Carlos Tomás Roura, C Tomás Roura, C Moll Turudi, Concepción Moll Turudi, Delia Taverner Torrent, D Taverner Torrent, Felipe Joaquín Rivas Santirso, FJ Rivas Santirso, Juan José Lerma Garrido, JJ Lerma Garrido, R García Portales, Rosa García Portales, Sergi Ordoñez Palau, S Ordoñez Palau, S Paredes González-Albo, Silvia Paredes González-Albo, A Gracia Pérez, Antonio Gracia Pérez, A Conesa Mateos, Arantxa Conesa Mateos, Jaime Calvo Alén, J Calvo Alén, Jenaro Graña Gil, J Graña Gil, María Pilar Navarro Alonso, MP Navarro Alonso, MJ Martínez Blasco, María Jesús Martínez Blasco, V Torrente-Segarra, Vicenç Torrente-Segarra, A Urruticoechea Arana, Ana Urruticoechea Arana, A Sánchez-Andrade, Amalia Sánchez-Andrade Fernández, JV Tovar, Juan Víctor Tovar Beltrán, A Muñoz, Alejandro Muñoz Jiménez, A Martínez, Anna Martínez-Cristóbal, JA González, José Antonio González Ferrández, Manuel Fernández Prada, M Fernández, N. Vázquez, Noelia Vázquez Fuentes, Hèctor Corominas, H Corominas, Sílvia García-Díaz, S García-Díaz, A Acosta-Pereira, Asunción Acosta Pereira, José Miguel Ruiz Martín, JM Ruiz Martín, JR Lamua Riazuelo, José Ramón Lamua Riazuelo, Rosa Expósito Moliner, R Expósito, Desireé Ruiz Vilchez, D Ruiz Vilchez, R Veiga Cabello, Raúl Veiga Cabello, J Carlos Fernández, Jesús Carlos Fernández, José Raúl Noguera Pons, JR Noguera Pons, N Patricia Garrido Puñal, Noemí Patricia Garrido Puñal, Pedro Giralt Celiméndiz, P Giralt Celiméndiz, Raúl Cortés Verdú, R Cortés Verdú, Angel Aragón Díez, A Aragón Díez, Carlos Tomás Roura, C Tomás Roura, C Moll Turudi, Concepción Moll Turudi, Delia Taverner Torrent, D Taverner Torrent, Felipe Joaquín Rivas Santirso, FJ Rivas Santirso, Juan José Lerma Garrido, JJ Lerma Garrido, R García Portales, Rosa García Portales, Sergi Ordoñez Palau, S Ordoñez Palau, S Paredes González-Albo, Silvia Paredes González-Albo, A Gracia Pérez, Antonio Gracia Pérez, A Conesa Mateos, Arantxa Conesa Mateos, Jaime Calvo Alén, J Calvo Alén, Jenaro Graña Gil, J Graña Gil, María Pilar Navarro Alonso, MP Navarro Alonso, MJ Martínez Blasco, and María Jesús Martínez Blasco
- Abstract
Objective: To assess effectiveness and safety of certolizumab PEGol (CZP) in rheumatoid arthritis (RA) patients after 12 months of treatment and to detect predictors of response.Methods: Observational longitudinal prospective study of RA patients from 35 sites in Spain. Variables (baseline, 3- and 12-month assessment): sociodemographics, previous Disease Modifying Anti-Rheumatic Drug (DMARD) and previous Biological Therapies (BT) use; TJC, SJC, ESR, CRP, DAS28, SDAI. Response variables: TJC, SJC, CRP, ESR, and steroids dose reductions, EULAR Moderate/Good Response, SDAI response and remission, DAS28 remission. Safety variables: discontinuation due to side-effects. Descriptive, comparative and Logistic regression analyses were performed.Results: We included 168 patients: 79.2% women, mean age 54.5 years (±13.2 SD), mean disease duration 7.5 years (±7.3 SD). Mean number of prior DMARD: 1.4 (±1.2 SD), mean number of prior BT was 0.8 (±1.1). Mean time on CZP was 9.8 months (±3.4 SD). A total of 71.4% were receiving CZP at 12-month assessment. Baseline predictors of response: lower prior number DMARD; low number prior BT; higher CRP, ESR, TJC, SJC, DAS28 and SDAI (p < 0.05) scores. A 25/46.4% Moderate/Good Response, a 20% SDAI remission, and a 44% DAS28 remission were observed. We observed 48 discontinuations (28.6%), 31 due to partial or complete ineffectiveness, and 17 due to side-effects.Conclusions: CZP showed benefit in severe RA patients, with significant reduction of all effectiveness parameters, despite the high prevalence of previous BT exposure in our series. We found CRP, ESR, prior DMARD/BT number, TJC, SJC, DAS28, and SDAI as baseline predictors of response. CZP was mostly well tolerated.
- Published
- 2015
- Full Text
- View/download PDF
8. RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database
- Author
-
Vicenç Torrente-Segarra, Ana Urruticoechea Arana, Amalia Sánchez-Andrade Fernández, Juan Víctor Tovar Beltrán, Alejandro Muñoz Jiménez, Anna Martínez-Cristóbal, José Antonio González Ferrández, Manuel Fernández Prada, Noelia Vázquez Fuentes, Hèctor Corominas, Sílvia García-Díaz, Asunción Acosta Pereira, José Miguel Ruiz Martín, José Ramón Lamua Riazuelo, Rosa Expósito Moliner, Desireé Ruiz Vilchez, Raúl Veiga Cabello, Jesús Carlos Fernández, José Raúl Noguera Pons, Noemí Patricia Garrido Puñal, Pedro Giralt Celiméndiz, Raúl Cortés Verdú, Angel Aragón Díez, Carlos Tomás Roura, Concepción Moll Turudi, Delia Taverner Torrent, Felipe Joaquín Rivas Santirso, Juan José Lerma Garrido, Rosa García Portales, Sergi Ordoñez Palau, Silvia Paredes González-Albo, Antonio Gracia Pérez, Arantxa Conesa Mateos, Jaime Calvo Alén, Jenaro Graña Gil, María Pilar Navarro Alonso, María Jesús Martínez Blasco, Vicenç Torrente-Segarra, Ana Urruticoechea Arana, Amalia Sánchez-Andrade Fernández, Juan Víctor Tovar Beltrán, Alejandro Muñoz Jiménez, Anna Martínez-Cristóbal, José Antonio González Ferrández, Manuel Fernández Prada, Noelia Vázquez Fuentes, Hèctor Corominas, Sílvia García-Díaz, Asunción Acosta Pereira, José Miguel Ruiz Martín, José Ramón Lamua Riazuelo, Rosa Expósito Moliner, Desireé Ruiz Vilchez, Raúl Veiga Cabello, Jesús Carlos Fernández, José Raúl Noguera Pons, Noemí Patricia Garrido Puñal, Pedro Giralt Celiméndiz, Raúl Cortés Verdú, Angel Aragón Díez, Carlos Tomás Roura, Concepción Moll Turudi, Delia Taverner Torrent, Felipe Joaquín Rivas Santirso, Juan José Lerma Garrido, Rosa García Portales, Sergi Ordoñez Palau, Silvia Paredes González-Albo, Antonio Gracia Pérez, Arantxa Conesa Mateos, Jaime Calvo Alén, Jenaro Graña Gil, María Pilar Navarro Alonso, and María Jesús Martínez Blasco
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.